Echinacea purpurea for COVID-19

AbstractIntroductionSARS-CoV-2 vaccination is effective in preventing severe COVID-19, but efficacy in reducing viral load and transmission wanes over time. In addition, the emergence of novel SARS-CoV-2 variants increases the threat of uncontrolled dissemination and additional antiviral therapies are urgently needed for effective containment. In previous in vitro studies Echinacea purpurea demonstrated strong antiviral activity against enveloped viruses, including SARS-CoV-2. In this study, we examined the potential of Echinacea purpurea in preventing and treating respiratory tract infections (RTIs) and in particular, SARS-CoV-2 infections.Methods120 healthy volunteers (m,f, 18 – 75 years) were randomly assigned to Echinacea prevention or control group without any intervention. After a run-in week, participants went through 3 prevention cycles of 2, 2 and 1 months with daily 2’400mg Echinacea purpurea extract (Echinaforce®, EF). The prevention cycles were interrupted by breaks of 1 week. Acute respiratory symptoms were treated with 4’000 mg EF for up to 10 days, and their severity assessed via a diary. Naso/oropharyngeal swabs and venous blood samples were routinely collected every month and during acute illnesses for detection and identification of respiratory viruses, including SARS-CoV-2 via RT-qPCR and serology.ResultsSummarized over all phases of prevention, 21 and 29 samples tested positive for any virus in the EF and control group, of which 5 and 14 samples tested SARS-CoV-2 positive (RR=0.37, Chi-square test, p=0.03). Overall, 10 and 14 symptomatic episodes occurred, of which 5 and 8 were COVID-19 (RR=0.70, Chi-square test, p>0.05). EF treatment when applied during acute episodes significantly reduced the overall virus load by at least 2.12 log10 or approx. 99% (t-test, p<0.05), the time to virus clearance by 8.0 days for all viruses (Wilcoxon test, p=0.02) and by 4.8 days for SARS-CoV-2 (p>0.05) in comparison to control. Finally, EF treatment significantly reduced fever days (1 day vs 11 days, Chi-square test, p=0.003) but not the overall symptom severity. There were fewer COVID-19 related hospitalizations in the EF treatment group (N=0 vs N=2).Discussion/ConclusionEF exhibited antiviral effects and reduced the risk of viral RTIs, including SARS-CoV-2. By substantially reducing virus loads in infected subjects, EF offers a supportive addition to existing mandated treatments like vaccinations. Future confirmatory studies are warranted.Clinical Trials registration NrNCT05002179

Echinacea purpurea has been shown to broadly inhibit coronaviruses and SARS-CoV-2 in vitro. This review discusses the available clinical evidence from randomized, blinded and controlled human studies. Two RCTs capturing incidence of viral respiratory tract infections during Echinacea preventative treatment were identified including coronavirus infections. Incidence and/or viral loads were measured by RT-PCR and symptom severity was recorded. In a first study, Jawad et al. collected nasopharyngeal swabs from adults (N = 755) over 4 months of continuous prevention. Overall, 24 and 47 enveloped virus infections occurred, including 21 and 33 coronavirus detections (229E; HKU1; OC43) with Echinaforce® extract (2400 mg daily) and placebo, respectively (p = 0.0114). In a separate study, Ogal et al. administered the same extract (1200 mg) or control for 4 months to children (4–12 years) (N = 203). Echinacea reduced the incidence of enveloped virus infections from 47 to 29 (p = 0.0038) whereas 11 and 13 coronavirus detections (229E, OC43, NL63) were counted (p > 0.05). Respiratory symptoms during coronavirus infections were significantly lower with area-under-curve AUC = 75.8 (+/−50.24) versus 27.1 (+/−21.27) score points (p = 0.0036). Importantly, viral loads in nasal secretions were significantly reduced by 98.5% in the Echinacea group, with Ct-values 31.1 [95% CI 26.3; 35.9] versus 25.0 [95% CI 20.5; 29.5] in the control group (p = 0.0479). Results from clinical studies confirm the antiviral activity found for Echinacea in vitro, embracing enveloped respiratory pathogens and therefore coronaviruses as well. Substantiating results from a new, completed study seem to extrapolate these effects to the prevention of SARS-CoV-2 infections. As hypothesized, the established broad antiviral activity of Echinacea extract appears to be inclusive for SARS-CoV-2.

This cross‐sectional study investigated nonconventional therapies for COVID‐19 in Trinidad, emphasizing the need for documentation supporting future pharmaceutical research. The survey, conducted from June 20 to July 19, 2022, garnered responses from 57 participants aged 18 and above, with 82.46% vaccinated. The majority (81%) utilized both conventional and nonconventional therapies, revealing insights for potential alternatives to traditional treatments. Conventional treatments, including antibiotics, Ivermectin, anti‐inflammatories, analgesics, bronchodilators, and cough/flu syrups, were frequently reported. Nonconventional therapies encompassed vitamins, minerals, supplements, and various plant and animal products. When participants used conventional therapies, either alone or in combination with nonconventional ones, 13.21% reported side effects. These included severe thirst, headache, nausea, drowsiness, and one case of weight gain. Conversely, those exclusively using nonconventional treatments reported no side effects. Encouragingly, nonconventional therapies demonstrated promising effects in managing COVID‐19, emphasizing the need for meticulous selection, research, and development of their bioactive compounds as potential alternatives to conventional therapies.

Desde o início da pandemia do novo coronavírus, houve grande preocupação diante de uma doença cujos possíveis impactos e morbidade ainda eram desconhecidos, iniciando, assim, uma corrida na descoberta de um tratamento para esta doença. Nesse sentido diversas pesquisas foram e estão sendo realizadas em busca de espécies vegetais passíveis de serem utilizadas na terapêutica da COVID-19. Portanto, esse estudo tem como objetivo realizar revisão de estudos etnodirigidos de espécies vegetais referenciadas na terapêutica e/ou prevenção da COVID-19. Foi realizada uma busca nas bases Scielo, LILACS e PubMed entre 2020 a 2022. Foram selecionados 32 artigos, predominando os de língua inglesa (n= 30), em 2021 (56,25%) e nos países Irã, Índia e Estados Unidos (15,62%); 86 espécies vegetais foram referidas, pertencentes a 51 famílias, com predomínio de Asteraceae e Laminaceae. As espécies mais referidas foram Glycyrrhiza glabra L. (4,65%) e Nigella sativa L. (3,48%), predominando o uso da raiz (29,4 %), preparadas como extrato aquoso (23,5%). Para futuros trabalhos, deve ser estimulada a continuidade dos estudos de validação com tais espécies, fundamentados na certificação de eficácia, segurança e qualidade; afim de minimizar os riscos do uso popular de produto inadequado e contribuir na pesquisa e desenvolvimento de um futuro bioproduto no tratamento do SARS-CoV-2.

Background: The outbreak of Coronavirus Disease 2019 (COVID-19) has originated from Wuhan, China and rapidly spread all over the world. This disease is caused by a coronavirus termed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that mainly infects the human respiratory tract. Herbal agents including Atractylodes lancea, Ephedra, Curcumin, and Echinacea purpurea had immunomodulatory effects and antiviral activities on other respiratory viruses including Influenza virus. They strengthen the innate immunity through increasing the phagocytic activity and antiinflammatory activity. These herbs could be used as a complementary therapy to prevent entry of COVID-19 and improve immune system. This review delves into the role and therapeutic compounds of various herbal agents in relation to immunity, their effectiveness in treating other viral respiratory illnesses, and their potential influence on COVID-19 disease.